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Chronic renal failure, parathyroid hormone and fatty acids oxidation in
skeletal muscle. Fatty acids are an important source of skeletal muscle
energy, and certain data suggest oxidation of long-chain fatty acids
(LCFA) may be impaired in uremia. This abnormality may in part be
responsible for uremic myopathy. Uremia is associated with hyperpara.
thyroldism and PTH affects muscle metabolism; PTH enhances muscle
proteolysis and impairs muscle bioenergetics, and it is possible that
PTH also affects fatty acids oxidation. The present study examined in
rats the effects of 4 days administration PTH and of 21 days of chronic
renal failure (CRF) with and without excess PTH on oxidation of LCFA
and short-chain fatty acids (SCFA). Both 1-84 and 1-34 PTH impaired
oxidation of LCFA but not of a SCFA (/3-hydroxybutyric acid) and
reduced the activity of carnitine palmitoyl transferase (CPT). Inactiva-
tion of the P'FH abolished its effects. CRF rats with intact parathyroid
glands had also impaired oxidation of LCFA and of CPT activity.
Parathyroidectomy in CRF rats normalized these abnormalities. Carni-
tine contents of muscle were not altered. The data show that PTH
excess in normal or in CRF rats is associated with impaired oxidation of
LCFA and this effect is due to reduction in the activity of CPT, a key
enzyme for the transport of LCFA to mitochondrial matrix for /3-
oxidation. The data demonstrate another toxic effect of PTH on muscle
in CRF and provide an additional pathogenic mechanism for uremic
myopathy.
Several lines of evidence indicate that skeletal muscle is a
target organ for parathyroid hormone (PTH). First, muscle
dysfunction is encountered in clinical states with excess PTH,
such as patients with primary hyperparathyroidism [1—3] and
those with chronic renal failure and secondary hyperparathy-
roidism [4, 5]. Second, Garber [6] found that both intact PTH
and its amino-terminal fragment affect muscle protein, and
aminoacids metabolism. The hormone enhances muscle prote-
olysis and increases the release of alanine and glutamine. Third,
Baczynski et al [7] demonstrated that PTH affects bioenergetics
of skeletal muscle in that it inhibits energy production, transfer
and utilization. Finally, Palmieri et al [8] reported that PTH
plays a role in the muscle dystrophy of the hamster, and
parathyroidectomy was followed by improvement of the mus-
cular lesion.
Fatty acids provide an important source of energy for skeletal
muscle [9] and the integrity of the process involved in their
Received for publication June 4, 1987
and in revised form September 24, 1987
© 1988 by the International Society of Nephrology
oxidation is important for the normal function of the muscular
cell. Certain clinical observations suggest that oxidation of fatty
acids may be impaired in uremia [10], and such an abnormality
would provide another mechanism for the muscular dysfunction
in chronic renal failure. Since uremia is associated with second-
ary hyperparathyroidism and excess blood levels of PTH [11—
14], it is theoretically, possible that the excess blood levels of
P1'H in uremia affects fatty acids oxidation.
The present study was undertaken to examine the effect of
PTH and of uremia with and without excess PTH on the
oxidation of short- and long-chain fatty acids by skeletal mus-
cle.
Methods
Male Sprague-Dawley rats weighing 250 to 280 g were used in
the study. The animals were fed normal rat chow (ICN Nutri-
tional Biochemical, Cleveland, Ohio, USA) throughout the
study. Previous studies in our laboratory showed that a clear
cut effect of PTH on mitochondrial oxygen consumption occurs
after four days of treatment with the hormone [7]. Therefore,
the present study utilized the four day protocol of PTH treat-
ment. The animals were housed in individual cages.
The rats received an intraperitoneal injection of 200 U/day of
1-84 PTH and 200 or 300 U/day of 1-34 PTH (Sigma Chemical
Company, St. Louis, Missouri, USA) for four days. The
hormone was dissolved in normal saline, and half of the daily
dose was given in the morning and the other half in the late
afternoon hours. The control animals received sham injections
containing the vehicle (saline) only. Another group of animals
were treated with 200 U/day of inactivated 1-84 PTH for four
days. The inactivation of 1-84 PTH was done as follows: 10 to
15 sJg of PTH was dissolved in 60 .d 0.15 N acetic acid, and 40
.tlof 30% vol/vol H202 were added to this solution. The solution
was incubated at 37°C for 45 minutes, and the reaction was
terminated by freezing, which was followed by lyophilization.
Fatty acids oxidation, a-ketoglutarate oxidation, activity of
carnitine palmitoyl transferase and carnitine content were ex-
amined on the morning of day 5.
Studies were also performed after 21 days of chronic renal
failure in the presence and absence of the parathyroid glands.
Parathyroidectomy (PTX) was performed by electrocautery,
and the success of the procedure was ascertained by a decrease
in serum levels of calcium of at least 2 mg/dl. The rats were
allowed to freely drink water containing 50 g/liter of calcium
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gluconate. This procedure is adequate to normalize plasma
calcium in PTX rats. Seven days after PTX, the animals
underwent right partial nephrectomy through a flank incision; a
week later, a left nephrectomy was performed. The nephrec-
tomy procedures were also performed in rats with intact para-
thyroid glands. Thus, this protocol provided two groups of
animals with chronic renal failure (CRF): one with intact
parathyroid glands (CRF-control) and the other without para-
thyroid glands (CRF-PTX). Studies of fatty acids oxidation,
a-ketoglutarate oxidation, carnitine palmitoyl transferase activ-
ity and carnitine content were done on the morning of day 22.
Studies were also performed in normocalcemic parathyroidec-
tomized rats with normal renal function (normal-PTX) and the
experiments were done 22 days after parathyroidectomy.
The animals were sacrificed by decapitation, and skeletal
muscles from the hind limb (gastrocnemius and biceps) were
removed and washed of blood. One piece was frozen with liquid
nitrogen and kept at —70°C for the measurement of carnitine,
The other piece of muscle was used for the isolation of
mitochondna according to the method of Yang, Gieger and
Bessman [15]. About 3 to 4 g of muscle was placed in an
ice-cold homogenization media containing 180 mri KCI, 10 mM
EDTA disodium with a pH adjusted to 7.4. The tissue was then
cut into small pieces, run through a Harvard tissue press and
treated for seven minutes with trypsin and then homogenized
with a Dounce type homogenizer. A trypsin inhibitor was then
added to stop the reaction. The mixture was diluted threefold
with the homogenization media and then centrifuged for 10
minutes, at 400 g, in a Sorvall RC-5 refrigerated centrifuge
(DuPont Co., Instrument Product Division, Newton, Connect-
icut, USA). The pellet was discarded and the supernatant was
centrifuged at 8000 g for 10 minutes, for final isolation of the
mitochondria. The mitochondrial pellet was washed several
times and suspended in media containing 180 mM KCI, 10 mM
Tris He! and 0.5% (wt/vol) dialyzed albumin. The pH of the
media was 7.4. The protein concentration of the mitochondrial
pellet was determined by a modification of the method of Lowry
et a!. [161. The isolated mitochondria were used for the study of
a-ketoglutarate and fatty acids oxidation, and for the activity of
the carnitine palmitoyl transferase. The substrate oxidation rate
and ADP:O ratio were determined polarographically by means
of a Clark oxygen electrode (Gilson Medical Electronics, Mid-
dieton, Wisconsin, USA), fitted to a plexiglas chamber of 2.0 ml
capacity as described originally by Chance and Williams [17].
The details for the study of a-ketoglutarate oxidation have been
previously reported from our laboratory [7]; 520 jimol of ADP
was added each time to the oxygraph chamber. The complete
system for fatty acid oxidation contajned between 1.0 and 1.5
mg mitochondrial protein added to 2 ml of incubation media
containing (in mM): 250 mannitol, 10 KC1, 10 Tris HC1, 0.1
EDTA disodium and 5 potassium phosphate. The final pH was
7.2 and the temperature 28°C. For the study of short-chain fatty
acids oxidation, about 1.0 to 1.5 mg of mitochondna protein
contained in lOOl and 50 d of 16 mM p-hydroxybutyric acid
were added to the incubation media in the oxygraph chamber.
The studies for the evaluation of the long-chain fatty acids
oxidation utilized activated fatty acid palmitoyl CoA (Sigma
Chemical Co.). To prepare this fatty acid for use in the study, 1
mg of palmitoyl CoA was added to 1 ml of 96% ethanol and
sonicated for 10 to 15 minutes, and then diluted with 9 ml of
distilled water. The same oxygraph media was used as that
employed for the short-chain fatty acids studies. About 1.0 to
1.5 mg mitochondrial protein contained in 100 d, 50 jtl of 2 mM
of LD-carnitine and 30 .d of 0.1 mri palmitoyl CoA were added
to the incubation chamber. Oxygen consumption was recorded
and results were calculated according to Chance and Williams
[17] and expressed as nanomoles of oxygen per milligram of
protein per minute.
The activity of carnitine palmitoyl transferase was measured
by the method of Bieber, Abraham and Helmarth [18]. This
enzyme activity is determined by the release of free CoA in the
presence of exogenous L-carnitine, palmitoyl CoA and 5.5'-
dithiobis-(2 nitrobenzoate) (DTNB). The free CoA reduces
DTNB giving a yellow color which has a molar absorbance per
centimeter of 13.6 x lO at 412 nm and at pH 8.0. To eliminate
the effect of endogenous mitochondrial L-carnitine on the
result, a parallel assay is run with excess D-carnitine which
inhibit the reaction (blank); the activity of the enzyme is then
calculated as the difference between results observed in the
presence of L- and D-carnitine and expressed as nanomoles of
CoA per milligram protein per minute. Carnitine was measured
by the methods of Cederblad and Lindstedt [19] and of Borum,
York and Bennett [201; non-collagen protein was determined by
the methods of Lilienthal et al [21] and Itzhaki and Gill [22]. The
results are expressed as nmol/mg non-collagen protein.
In all studies, blood samples were obtained for the measure-
ments of calcium with atomic absorption spectrophotometer
(Model 505, Perkin Elmer Corporation, Norwalk, Connecticut,
USA) and for inorganic phosphorus and creatinine with an
autoanalyzer (Technicon Corp. Terrytown, New York, USA).
Data are expressed as mean SE and statistical significance
was evaluated by parametric t-test.
Results
The treatment of rats for four days with 1-84 or 1-34 PTH did
not cause a significant rise in the blood levels of calcium
(normal: 9.6 0.2 mgldl; 1-84 PTH: 9.9 0.2 mg/dl; 1-34 PTH
[200 U] 10.0 0.40 mg/dl; 1-34 PTH [300 U]: 9.7 0.2 mgldl).
In contrast, PTH treatment was associated with a significant (P
<0.01) reduction in the blood levels of inorganic phosphorus
(normal: 7.6 0.3 mgldl; 1-84 PTH 6.3 0.3 mgldl; 1-34 PTH
(200 U): 6.2 0.2 mgldl; 1-34 PTH (300 U): 6.3 0.20). There
were no significant changes in the blood levels of creatinine
after PTH injections and values were not different from normal
(0.51 + 0.2 mgldl).
The effects of 1-84 and 1-34 PTH on mitochondrial fatty acids
oxidation and the activity of carnitine palmitoyl transferase are
presented in Table 1 and Figures 1 to 3. The respiratory control
ratio of the skeletal muscle mitochondria in all groups of
animals were within the range of intact coupled mitochondria.
There were no significant differences in the ADP:O ratios
between the normal rats and those treated with PTH. The
treatment with 200 U of 1-84 PTHIday for four days produced a
significant reduction in mitochondnal oxygen consumption with
a-ketoglutarate as substrate (normal: 183 4.2 vs. 1-84 PTH:
141 3.9 nmol Oz/mg protein/mm, P < 0.01), a significant
impairment of long chain fatty acids oxidation (normal: 60 3.5
vs. 1-84 PTH: 33.4 + 2.0 nmol 02/mg protein/mm, P < 0.01,
Fig. 1) and significant reduction in the activity of carnitine
palmitoyl transferase (normal: 15.1 0.83 vs. 1-84 P1'H: 9.8 ±
>
. .(5'0.0
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Table 1. Effect of 1-84 PTH, inactivated 1-84 PTH, and 1-34 PTH on the oxidation of short-chain and long-chain fatty acids and on the activity
of carnitine palmitoyl transferase of skeletal muscle mitochondria
Inactivated
1-84 PTH 1-84 PTH 1-34 PTH 1-34 PTH
Normal (6) 200 U (6) 200 U (6) 200 U (6) 300 U (6)
Respiratory control ratio 12.3 1.01 11.3 0.7 12.5 1.10 9.7 0.60 10.1 1.90
ADP/O 3.0 0.11 2.89 0.09 2.9 0.10 2.9 0.11 3.0 0.12
Oxygen consumption
nmolesO2lmg protein/mm 183 4.2 141 39a 190 2.6 187 4.1 152 3.1
a-ketoglutarate
/3-hydroxybutyric acid 24 2.7 25.0 1.0 24 2.0 27 1.6 21 1.1
Palmitoyl Co A 60 3.5 33.4 2.Oa 63 3.8 60 3.5 34 3.2a
Carnitine palmitoyl transferase
nmol CoA/mg protein/mm 15.1 0.83 9.8 0.25a 16.2 1.31 15.0 1.00 10.9 0.62a
200
a-KG L-C FA S-C FA
Data are presented as mean SE.
Data in brackets represent the number of rats studied.
a P < 0.01 vs. normal
C0
0.
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Fig. 1. Effects of administration of 1-84 PTH (U) or inactivated
hormone () to normal (El]) rats on oxygen consumption by their
skeletal muscle mitochondria utilizing a-ketoglutarate (a-KG), long
chain (L-CFA) and short chain (S-CFA) fatty acids. Each column
represent mean value and brackets denote 1 SE.
200
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0
ig. 2. Effects of administration of 1-84 PTH (U), inactivated hormone
I) and 1-34 PTH (111 200 U; 300 U) to normal (U) rats on the activity
fcarnitine palmitoyl transferase of their skeletal muscle mitochondria.
ach column represent mean value and brackets denote I SE.
0.25 nmoles C0A/mg protein/mm, P < 0.01, Fig. 2). Inactiva-
tion of 1-84 PTH abolished the effect of the hormone on oxygen
consumption with a-ketoglutarate, long-chain fatty acids oxida-
a-KG L-C FA S-C FA
2000
a.
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>-O, 100
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Fig. 3. Effects of administration of 200 () and 300 (U) U of 1-34 PTH
to normal (U) rats on oxygen consumption by their skeletal muscle
mitochondria utilizing a-ketoglutarate (a-KG) long chain (L-C FA) and
short chain (S-C FA) fatty acids. Each column represent mean value
and brackets denote I SE.
tion and on carnitine palmitoyl transferase activity (Fig. 1 and
2). Treatment with 200 U of 1-34 PTH for four days had no
effect on these parameters while the administration of 300 U of
1-34 PTH/day for four days impaired significantly (P < 0.01) the
oxidation of a-ketoglutarate (183 4.2 vs. 152 3.1 nmol
02/mg protein/mm, Fig. 3) and of palmitoyl CoA (60 3.5 vs.
34 3.23 nmol 02/mg protein/mm, Fig. 3) and of the activity of
carnitine palmitoyl transferase (15.1 0.83 vs. 10.9 0.62
nmol CoA/mg protein/mm, Fig. 2). Treatment with 1-84 or 1-34
PTH did not affect mitochondrial oxidation of the short-chain
fatty acids (/3-hydroxybutyric acid).
The nephrectomy procedure resulted in a significant (P <
0.01) rise in the serum levels of creatinine with the levels being
three times higher than normal (Table 2). There was no signif-
icant difference between the serum levels of calcium in CRF-
control and CRF-PTX rats and the values were not different
from those in normal and normal-PTX animals. The serum
levels of inorganic phosphorus were not different among the
CRF-control, CRF-PTX and normal PTX rats, but the values
were significantly lower than those in normal rats.
The effects of CRF with and without parathyroid glands and
of PTX in rats with normal renal function on fatty acids
oxidation and on the activity of carnitine palmitoyl transferase
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Table 2. Effect of chronic renal failure with and without parathyroid glands and of parathyroidectomy in rats with normal renal function on the
oxidation of short-chain and long-chain fatty acids and on the activity of carnitine palmitoyl transferase of skeletal muscle mitochondria
Normal
Normal (6) CRF control (6) CRF-PTX (6) VFX (6)
Serum calcium mg/dl 9.6 0.2 9.0 0.4 9.4 0.4 8.9 0.3
Serum phosphorus mg/dl 7.6 0.3 5.9 0.7a 6.5 0.3 6.1 O.3
Serum creatinine mgldl 0.51 0.02 1.55 0.19a 1.62 0.24a 0.52 0.01
Respiratory control ratio 12.3 1.01 11.5 0.46 11.1 0,82 11.4 0.86
ADP/O 3.0 0.11 2.9 0.08 2.8 0.08 2.8 0.10
Oxygen consumption
nmol O2Img protein/mm
a-ketoglutarate 183 42 148 4.8a 187 6.0 192 4.6
f3-hydroxybutyric acid 24 2.7 19 2.1 18 1.3 21 0.9
Palmitoyl Co A 60 3.5 32 1.5a 53 2.0 55 2.2
Carnitine palmitoyl transferase
nmol/mg protein/mm 15.1 0.83 11.8 0.29 14.7 0.96 14.8 0.38
Data are presented as mean SE. Data in brackets represent the number of rats studied.
P < 0.01 vs. control
C0
200E .
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Fig. 4. Oxygen consumption by skeletal muscle mitochondria from
normal rats (D), animals with chronic renal failure (U), normocalce-
mic-parathyroidecto,nized rats with CRF () and normocalcemic-
parathyroidectomized rats with normal renal function (Ill). Three sub-
strates were used including a-ketoglutrate (a-KG), long chain (L-C PA)
and short chain (S-C FA) fatty acids, Each column represents mean
value and brackets denote 1 SE.
are given in Table 2 and Figures 4 and 5. The respiratory control
ratio of the skeletal muscle mitochondria in all groups of
animals were within the range of intact coupled mitochondria.
There were no significant differences in the ADP:O ratios
between the normal rats, CRF-control animals, CRF-PTX rats
and normal-PTX rats, In CRF-control animals, oxidation of
a-ketoglutarate (148 4.8 nmol 02/mg protein/mm) and of
palmitoyl CoA (32 1.5 nmol 02/mg protein/mm) were signif-
icantly (P < 0.01) lower than that in normal (183 4.2 and 60
3.5 nmol 02/mg protein/mm, respectively), Figure 4. Also the
activity of carnitine palmitoyl transferase was significantly (P <
0.01) reduced in CRF-control rats (11.8 0.2 nmol CoA/mg
protein/mm) as compared to normal animals (15.1 0.83 nmol
CoA/mg protein/mm), Figure 5. Parathyroidectomy in CRF rats
resulted in normalization of the oxidation of a-ketoglutarate and
of palmitoyl CoA as well as the activity of carnitine palmitoyl
transferase (Fig. 4 and 5). Parathyroidectomy in rats with
normal renal function had no effects on these parameters. The
oxidation of the /3-hydroxybutyric acid, a short chain fatty acid,
in CRF-control, CRF-PTX, normal-PTX rats were not different
from that in normal animals.
Carnitine contents of skeletal muscle of the various groups of
0
10
EE
0.0
.E '
0
Fig. 5. Carnitine palmitoyl transferase activity of skeletal muscle
mitochondria from normal rats (D), animals with chronic renal failure
(U), norinocalcemic-parathyroidectomjzed rats with CRF () and
normocalcemic-parathyroidectomized rats with normal renal function
(Ill). Three substrates were used including a-ketoglutarate (a-KG), long
chain (L-C PA) and short chain (S-C FA) fatty acids. Each column
represents mean value and brackets denote 1 SE.
animals are shown in Figure 6. There were no significant
changes in the carnitine content and the values were not
different from normal.
Discussion
The results of the present study demonstrate that PTH exerts
an additional action on muscle metabolism to those already
reported [6—8]. The data show that the hormone inhibits oxida-
tion of long-chain fatty acids and as such interferes with the
usage of an important source of energy for skeletal muscle
function.
Several steps are involved in the oxidation of long chain fatty
acids by mitochondria [23], Figure 7. First, the fatty acid (FA)
such as palmitoyl in the presence of CoA, ATP and acyl-C0A
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synthetase penetrate the outer membrane of the mitochondria
and reaches the intermediate space as FA CoA. This compound
in the presence of carnitine and carnitine palmitoyl transferase
is converted into FA-carnitine and CoA. The FA-carnintine
transverses the inner membrane of the mitochondria, a process
which is facilitated by acyl carnitine translocase. In the matrix
of the mitochondria, FA-carnitine is again converted into FA
CoA and carnitine by carnitine palmitoyl transferase. The FA
CoA enters the /3-oxidation step. Thus, the inhibition of the
oxidation of long-chain fatty acids by PTH could be the results
of an interference by the hormone in any of these steps.
Our study also showed that PTH does not affect the oxidation
of f3-hydroxybutyric acid, a short chain fatty acid by mitochon-
dna. This process requires CoA but not acyl carnitine transfer-
ase and its final step involves /3-oxidation sequence (Figure 8).
One can, therefore, suggest that the effect of PTH on the
oxidation of long chain fatty acids is not mediated through an
effect on CoA and, hence, not on any of the steps where CoA is
involved nor on the /3-oxidation process; however, it is possible
that these processes are also involved since succinyl-CoA may
be the source of CoA for /3-hydroxybutyric acid activation and
only the terminal portion of /3-oxidation is involved in /3-hy-
droxybutyric acid oxidation. The action of PTH on long chain
fatty acid oxidation could also be due to an effect on the
Fig. 8. Schematic presentation of the various steps involved in the
oxidation of short-chain fatty acids by mitochondria.
availability of carnitine and/or to impairment of the activity of
carnitine palmitoyl transferase. Our data showed that the car-
nitine content of skeletal muscle is not reduced by PTH
administration, but the activity of carnitine palmitoyl transfer-
ase is impaired. Thus, the hormone interferes with a key step
required for the transfer of the long chain fatty acids from the
intermediate space of the mitochondria to its matrix.
The demonstration that the inactivation of 1-84 PTH abol-
ished its effects on the oxidation of long chain fatty acids and on
the activity of carnitine palmitoyl transferase is consistent with
the notion that these actions are related to the biological activity
of the hormone and not to a contaminant in its preparation.
Further support for this notion is provided by the finding that
1-34 PTH which is a synthetic and pure preparation also
impaired both processes. It is of interest that a greater dose of
1-34 PTH than of 1-84 PTH was required to exert an effect on
the oxidation of long-chain fatty acids and on the activity of
carnitine palmitoyl transferase. This is not surprising since pre-
vious studies showed similar observations on the effects of these
two moieties of the hormone on isolated heart cells [24] and on
myocardial bioenergetics [25]. This may suggest that other parts
of the intact PTH beside the amino terminal fragment (1-34
PTH) has biological activity.
The results of the present study also demonstrate that CRF in
rats with intact parathyroid glands is associated with inhibition
of oxidation of long chain fatty acids but not of /3-hydroxybu-
tyric a short-chain fatty acid and with reduction of the activity
of carnitine palmitoyl transferase. Thus, it appears that CRF,
like PTH treatment, also inhibits the key step of the transfer of
FA from the intermediate space to the matrix of the mitochon-
dna.
It has also been shown that CRF is associated with hyper-
plasia of the parathyroid glands in many species including man
[11, 12, 14], dogs [26] and rats [271. Although the blood levels of
PTH in our animals were not measured, it is reasonable to
assume that a state of secondary hyperparathyroidism did
develop in the rats with CRF and intact parathyroid glands. Our
data, therefore, are consistent with the notion that the derange-
ments in the oxidation of long-chain fatty acids in CRF rats are
due to excess PTH, although other consequences of CRF may
also play a role. The finding that normocalcemic CRF-PTX rats
Inner
membrane
Outer Intermembrane
membrane space
Normal Normal CRF CRF PTX 1—84 1—34
PTX PTH 300 U PTH
Matrix
— FA \FA CoA
CoA + ATP AMP + PP
13-OXIDATION
C
EE
C.)
Fig. 6. Carnitine content of skeletal muscle of various group of rats.
Each column represents mean value and brackets I SE.
outer intermembrane inner
membrane space membrane matrix
Palmitoyl CoA
PmitoyIL. AMP + PP.
ACS — AcyI-C0A synthetase
CPT-A + CPT-B = carnitine palmitoyltransferase
Fig. 7. Schematic presentation of the various steps involved in the
oxidation of long chain fatty acids by the mitochondria.
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had normal oxidation of long-chain fatty acids and normal
activity of carnitine palmitoyl transferase is in agreement with
the abnormalities in these processes in CRF-control rats are due
to excess PTH and not uremia. Parathyroidectomy, per se, does
not affect these processes as demonstrated by normal oxidation
of fatty acids and normal activity of carnitine palmitoyl trans-
ferase in the normocalcemic-PTX rats with normal renal func-
tion.
The mechanisms through which PTH exerts it effect on the
oxidation of long-chain fatty acids are not evident from the
present study. However, it has been shown previously in our
laboratory that PTH increases calcium uptake by skeletal
muscle and this change is responsible for inhibition of mito-
chondrial oxidation of a-ketoglutarate and impairment of the
activity of mitochondrial enzymes (creatine kinase and magne-
sium ATPase) [7]. Indeed, treatment with verapamil, a calcium
channel blocker, abolished this action of PTH. In the present
study, the oxidation of a-ketoglutarate was also inhibited by
PTH. It is, therefore, possible that an increase in the uptake of
calcium by skeletal muscle is also responsible for the effect of
the hormone on oxidation of long-chain fatty acids. CRF is also
associated with increased uptake of calcium by tissues such as
the myocardium and PTX reverses this change [28]. The
findings in our study of impaired long-chain fatty acids oxida-
tion in rats with CRF and intact parathyroid glands and the
reversal of this derangement by PTX are consistent with the
effect of PTH being mediated by increased calcium uptake by
the skeletal muscle.
The data of the present study provide evidence that PTH
affects another aspect of skeletal muscle metabolism besides its
effect on protein metabolism [6] and on energy production,
utilization and transfer [7]. These observations enlarge the
scope of the toxicity of excess PTH in uremia and provide an
additional mechanism for the myopathy of CRF.
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